CA 19-9, Cyfra 21-1, the ROMA score and HPV typing are the markers the upper programs add on top of the standard four. They narrow the questions the basic panel leaves open, and not one of them can find a cancer on its own.
CA 19-9 for the pancreas and bile ducts, Cyfra 21-1 for the lung, ROMA for ovarian risk, and HPV typing for cervical risk.
Hanaro's Bronze program, men's price, ≈₩660,000.
MediOne's Respiratory program, ≈₩700,000, alongside a sputum test and latent TB.
Hanaro's Gold program, ≈₩2,000,000, women's programs.
One week is the earliest an imaging slot can be held, and there is no referral step before it.
English report in your hands in about a week. You also get a consultation on preliminary findings on the day of the screening, before you leave.
Programme contents and prices from each partner centre's own foreigner-facing published list, read 2026-08-05: KMI Global, Hanaro Medical Foundation's English site and MediOne's English site. Standalone per-test prices are MediOne's 비급여 (non-covered) posting, the itemised list 의료법 제45조 requires a clinic to publish, read the same day. Scheduling and report turnaround are Meridiko's own operating figures, confirmed 2026-08-06, not a centre's published ones (https://global.kmi.or.kr/examination/foreigner_examination; https://en-mobile.hanaromf.com/program/prog01/prog01_01.jsp; https://en.medionemedicalcenter.com/m1; https://medionemedicalcenter.com/115), measured 2026-08-05.
CA 19-9 is used for pancreatic and biliary disease, Cyfra 21-1 for non-small-cell lung cancer, and the ROMA score combines CA-125 and HE4 into an ovarian-risk estimate that performs better than either alone. HPV typing identifies the viral strains that cause almost all cervical cancer, which is a genuine risk test rather than a marker.
Markers rise in benign disease and sit normal in early cancer. CA 19-9 in particular is raised by anything that obstructs bile, including gallstones. Used as a screening test in someone with no symptoms and no risk factors, a marker panel generates far more anxiety than findings.
Suits: People with a specific family history the marker matches, women wanting the stronger ovarian estimate rather than CA-125 alone, and anyone due for cervical screening who wants HPV typing with it rather than cytology alone.
Should not have it: Anyone treating a marker panel as a whole-body cancer check. That is what the imaging in these programs is for, and a normal marker set alongside no imaging is the least reassuring combination available.
The standard four markers in every entry program (AFP, CEA, CA-125 or PSA) cover the common ground. These four are targeted additions, and HPV typing is the odd one out: it is not a tumour marker at all but a test for the cause, which is why it has the clearest action attached.
Not itemised on the three tiers this site prices. CA 19-9 appears from Hanaro's Bronze, Cyfra 21-1 in MediOne's Respiratory program and Hanaro's Gold, and the ROMA score and HPV typing in Hanaro's Gold women's programs. Ask for the marker by name rather than assuming a tier includes it.
